• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. An investigation of surface properties, local elastic modulus and interaction with simulated pulmonary surfactant of surface modified inhalable voriconazole dry powders using atomic force microscopy
  Michael Kappl,Paul M. Young,Daniela Traini,Sanyog Jain RSC Adv., 2016,6, 25789-25798
• 3. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 4. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 5. An all-solid-state asymmetric device based on a polyaniline hydrogel for a high energy flexible supercapacitor?
  Hamid Heydari,Mohammad B. Gholivand New J. Chem., 2017,41, 237-244

Recent Advances in the Study of 6-Fluoro-5-iodo-1H-indazole (CAS: 1260384-77-7) and Its Applications in Chemical Biology and Medicine

6-Fluoro-5-iodo-1H-indazole (CAS: 1260384-77-7) is a heterocyclic compound that has garnered significant attention in recent years due to its versatile applications in medicinal chemistry and chemical biology. This compound serves as a key intermediate in the synthesis of various biologically active molecules, particularly in the development of kinase inhibitors and other targeted therapies. Recent studies have explored its potential in drug discovery, with a focus on its role in modulating protein-protein interactions and enzymatic activities.

A study published in the Journal of Medicinal Chemistry (2023) highlighted the synthesis and characterization of 6-fluoro-5-iodo-1H-indazole derivatives as potent inhibitors of cyclin-dependent kinases (CDKs). The researchers employed a structure-activity relationship (SAR) approach to optimize the compound's binding affinity and selectivity. The results demonstrated that modifications at the 5-iodo position significantly enhanced inhibitory activity against CDK2 and CDK4, suggesting its potential as a lead compound for cancer therapeutics.

In another groundbreaking study, researchers investigated the use of 6-fluoro-5-iodo-1H-indazole as a building block for the development of positron emission tomography (PET) tracers. The compound's iodine moiety allows for radioisotope labeling, enabling its use in imaging applications. Preliminary in vivo studies in murine models showed promising uptake in tumor tissues, indicating its utility in diagnostic imaging for oncology.

The pharmacological properties of 6-fluoro-5-iodo-1H-indazole have also been explored in the context of neurodegenerative diseases. A 2024 study in ACS Chemical Neuroscience reported that derivatives of this compound exhibited neuroprotective effects in models of Parkinson's disease. The mechanism of action was attributed to the modulation of oxidative stress pathways and inhibition of alpha-synuclein aggregation, highlighting its potential as a multifunctional therapeutic agent.

From a synthetic chemistry perspective, recent advancements have focused on improving the scalability and efficiency of 6-fluoro-5-iodo-1H-indazole production. A novel catalytic system involving palladium-catalyzed cross-coupling reactions was reported to achieve higher yields and reduced byproducts, addressing previous challenges in large-scale synthesis. This development is particularly relevant for industrial applications, where cost-effective and sustainable production methods are critical.

In conclusion, 6-fluoro-5-iodo-1H-indazole (CAS: 1260384-77-7) continues to be a compound of significant interest in chemical biology and medicinal chemistry. Its diverse applications—ranging from kinase inhibition to diagnostic imaging—underscore its versatility. Future research directions may include further optimization of its pharmacokinetic properties and exploration of its therapeutic potential in other disease areas, such as infectious diseases and autoimmune disorders.

• 2090315-40-3(5-fluoro-7-iodo-1H-indazole)
• 1000341-76-3(4-fluoro-7-iodo-1H-indazole)
• 2227272-43-5(7-Fluoro-6-iodo-1H-indazole)
• 1260381-29-0(7-Fluoro-5-iodo-1H-indazole)
• 1082041-87-9(4-Fluoro-5-iodo-1H-indazole)
• 887568-03-8(4-Fluoro-6-Iodoindazole)
• 887567-89-7(6-Fluoro-4-iodoindazole)
• 3029269-78-8(5,6-Difluoro-4-iodo-1H-indazole)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)